NFKB1 and neoplasm: In addition, the limited nuclear staining revealed with an anti-P65 NF-κB subunit Ab, evidenced a marked decrease in NF-κB activation in tumour cells of mice treated with both daunorubicin and rhGH, compared to the daunorubicin-treated group (P<0.0001) (Figure 5B).